Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/33518| Title: | Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial. | Austin Authors: | Dummer, Reinhard;Gyorki, David E;Hyngstrom, John R;Ning, Meng;Lawrence, Tatiana;Ross, Merrick I | Affiliation: | University Hospital of Zurich, Zurich, Switzerland. Olivia Newton-John Cancer Wellness and Research Centre University of Utah Huntsman Cancer Institute, Salt Lake City, Utah. Parexel, Guangzhou, Guangdong, China. Amgen Inc, Thousand Oaks, California. The University of Texas MD Anderson Cancer Center, Houston, Texas. Peter MacCallum Cancer Centre, Melbourne, Australia. |
Issue Date: | 10-Aug-2023 | Date: | 2023 | Publication information: | JAMA Oncology 2023-08-10 | Abstract: | This randomized clinical trial presents the final 5-year follow-up results of neoadjuvant talimogene laherparepvec (T-VEC) plus surgery in patients with advanced melanoma. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/33518 | DOI: | 10.1001/jamaoncol.2023.2789 | ORCID: | Journal: | JAMA Oncology | PubMed URL: | 37561473 | ISSN: | 2374-2445 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.